ANTI-S1 IMMUNOGLOBULINS AND IMMUNODIAGNOSTIC REAGENTS TO DETECT SARS-COV-2 ANTIGENS

| Written by Kevin Facun

INVENTORS

Dr. Salvador Eugenio Caoili, Dr. Fresthel Monica Climacosa, Dr. Ruby Anne King, Riziel Hannah Aguimatang, Ayra Patrice Espiritu

 

DESCRIPTION

The invention provides anti-peptide immunoglobulins that recognize epitopes of SARS-CoV-2 spike glycoprotein subdomain SD2, cognate oligopeptide-based immunogenic constructs suitable for producing said immunoglobulins, and methods for producing and utilizing said constructs and immunoglobulins.

 

VALUE PROPOSITION

  • New materials for diagnostics
  • For passive immunization to protect against and treat COVID-19
  • Helps in the production of vaccines for active immunization against COVID-19

 

MARKET APPLICATIONS AND COMMERCIAL OPPORTUNITIES

In 2020, SARS-CoV-2 was declared by the World Health Organization as a global pandemic. Numerous kits have been commercialized in the market as rapid diagnostic tests (RDTs) and other systems for the detection of SARS-CoV-2 antigens and anti-SARS-CoV-2 antibodies. This technology aims to enable the development of such systems and other biomedical applications (e.g., vaccines and therapeutic antibodies) using low-cost materials to be manufactured in the Philippines and elsewhere.

The technology presented can be utilized in R&D and clinical/molecular diagnostic laboratories, as well as for the development of novel vaccines and therapeutics.

 

DEVELOPMENT STATUS

The technology is currently in the laboratory stage and needs further research and development.

 

IP STATUS

Patent Application Filed

Application No. 1-2021-050442

 

TYPE OF PARTNERSHIP BEING SOUGHT

Licensing. Looking for partners or collaborators for clinical validation trials, licensees.